Process for the preparation of imatinib base
Provided is an environmentally-friendly process for preparing imatinib base in high yield, without the use of an organic solvent.
1. A process for preparing imatinib base comprising:
(a) condensing N-(2-methyl-5-aminophenyl-4-(3-pyridyl)-2-pyrimidine-amine and 4-(4-methylpiperazin-1-yl-methyl)benzoyl chloride dihydrochloride in the presence of a solvent to obtain imatinib hydrochloride; and
(b) combining the imatinib hydrochloride with a base to obtain imatinib base, wherein the solvent is not an organic solvent, and
wherein the base is an alkali metal hydroxide, alkali metal carbonate, or alkali metal bicarbonate.
2. The process of claim 1 , wherein the 4-(4-methylpiperazin-1-yl-methyl)benzoyl chloride dihydrochloride is present in a molar excess compared to the N-(2-methyl-5-aminophenyl-4-(3-pyridyl)-2-pyrimidine-amine.
3. The process of claim 1 , wherein the N-(2-methyl-5-aminophenyl-4-(3-pyridyl)-2-pyrimidine-amine and the 4-(4-methylpiperazin-1-yl-methyl)benzoyl chloride dihydrochloride are present in a molar ratio of about 1:1.5 to about 1:2.
4. The process of claim 1 , wherein the solvent is water.
5. The process of claim 1 , wherein the condensation is performed at a temperature of about 0° C. to about 10° C.
6. The process of claim 1 , wherein the condensation is performed by:
(i) combining the N-(2-methyl-5-aminophenyl-4-(3-pyridyl)-2-pyrimidine-amine and the solvent to form a mixture; and
(ii) adding the 4-(4-methylpiperazin-1-yl-methyl)benzoyl chloride dihydrochloride portion-wise to the mixture.
7. The process of claim 6 , wherein the 4-(4-methylpiperazin-1-yl-methyl)benzoyl chloride dihydrochloride is added to the mixture in portions of about 4% to about 8% over a period of about 2 to about 3 hours.
8. The process of claim 1 , wherein the base is an alkali metal hydroxide.
9. The process of claim 1 , wherein the base is present in an amount sufficient to achieve a pH of about 9 to about 10.
10. The process of claim 1 , wherein the imatinib hydrochloride is combined with the base at a temperature of about 40° C. to about 60° C.
11. The process of claim 1 , further comprising isolating the imatinib base.
12. The process of claim 11 , wherein the imatinib base is isolated in a yield of about 90% to about 99%.
13. The process of claim 11 , wherein the isolated imatinib base has a purity of about 90% to about 99% by weight.
14. The process of claim 11 , wherein the imatinib base is isolated in crystalline form.
15. The process of claim 11 , further comprising recrystallizing the isolated imatinib base.
16. The process of claim 15 , wherein the isolated imatinib base is recrystallized from ethyl alcohol.